Barclays reaffirmed their buy rating on shares of Qiagen (NASDAQ:QGEN) in a research note issued to investors on Thursday, September 6th. The firm currently has a $43.00 price target on the stock.

QGEN has been the subject of several other reports. Commerzbank reaffirmed a buy rating on shares of Qiagen in a report on Wednesday, July 25th. Citigroup raised their price objective on shares of Qiagen from $35.00 to $38.00 and gave the stock a neutral rating in a report on Thursday, August 2nd. BidaskClub upgraded shares of Qiagen from a sell rating to a hold rating in a research note on Wednesday, August 29th. Goldman Sachs Group reiterated a buy rating on shares of Qiagen in a research note on Wednesday, May 16th. Finally, DZ Bank reiterated a neutral rating on shares of Qiagen in a research note on Tuesday, June 5th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $38.33.

Shares of Qiagen stock traded down $0.72 on Thursday, reaching $37.51. 891,878 shares of the company traded hands, compared to its average volume of 957,862. Qiagen has a 52 week low of $30.20 and a 52 week high of $39.45. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.07 and a quick ratio of 4.59.

Qiagen (NASDAQ:QGEN) last released its quarterly earnings data on Tuesday, July 31st. The company reported $0.33 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.32 by $0.01. The company had revenue of $377.20 million during the quarter, compared to the consensus estimate of $376.89 million. Qiagen had a net margin of 2.85% and a return on equity of 11.74%. research analysts predict that Qiagen will post 1.34 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA boosted its holdings in Qiagen by 7.6% in the 1st quarter. BNP Paribas Arbitrage SA now owns 22,314 shares of the company’s stock worth $721,000 after buying an additional 1,579 shares during the period. Stephens Investment Management Group LLC boosted its holdings in Qiagen by 2.1% in the 1st quarter. Stephens Investment Management Group LLC now owns 107,972 shares of the company’s stock worth $3,489,000 after buying an additional 2,242 shares during the period. Toronto Dominion Bank boosted its holdings in Qiagen by 17.3% in the 2nd quarter. Toronto Dominion Bank now owns 17,214 shares of the company’s stock worth $627,000 after buying an additional 2,539 shares during the period. First Bank & Trust boosted its holdings in Qiagen by 156.0% in the 2nd quarter. First Bank & Trust now owns 4,928 shares of the company’s stock worth $178,000 after buying an additional 3,003 shares during the period. Finally, First Mercantile Trust Co. boosted its holdings in Qiagen by 28.2% in the 1st quarter. First Mercantile Trust Co. now owns 15,200 shares of the company’s stock worth $491,000 after buying an additional 3,348 shares during the period. Hedge funds and other institutional investors own 62.23% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

See Also: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for Qiagen (NASDAQ:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.